Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV000622358 | SCV000740762 | uncertain significance | Inborn genetic diseases | 2014-10-09 | criteria provided, single submitter | clinical testing | The c.5414A>G (p.E1805G) alteration is located in exon 34 (coding exon 33) of the PKHD1 gene. This alteration results from a A to G substitution at nucleotide position 5414, causing the glutamic acid (E) at amino acid position 1805 to be replaced by a glycine (G). The heterozygous missense change is ultra rare in healthy individuals: Based on data from the NHLBI Exome Sequencing Project (ESP), the PKHD1 c.5414A>G alteration was observed in 1 among 13006 total alleles studied (0.01%). Allele frequency data for this nucleotide position are not currently available from the 1000 Genomes Project. Based on data from the Genome Aggregation Database (gnomAD), the c.5414A>G alteration was observed among 0.004% (10/276,556) of total alleles studied, having been observed in 0.02% (1/6456) Other ethnicity alleles, 0.006% (7/126,174) Non-Finnish European alleles, and 1 allele in 23,972 African alleles and 34,400 Latino alleles each. Though some variants may appear to be rare due to database-specific ethnic underrepresentation, rare missense alleles commonly exhibit a deleterious effect on protein function (Kryukov, 2007; Tennessen, 2012). A nearby amino acid change has been observed in affected individuals: A missense change in the nearby amino acid (R1804C), in combination with a second splice alteration, was reported in a French patient with a fetal presentation of ARPKD (Sharp, 2005). The altered amino acid is not conserved throughout evolution: The p.E1805 amino acid is not well conserved in available vertebrate species. The alteration is predicted benign by in silico models: The p.E1805G alteration is predicted to be benign by Polyphen and tolerated by SIFT in silico analyses. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
| Fulgent Genetics, |
RCV002477364 | SCV000897296 | uncertain significance | Polycystic kidney disease 4 | 2022-03-01 | criteria provided, single submitter | clinical testing | |
| Mayo Clinic Laboratories, |
RCV003480716 | SCV004227252 | uncertain significance | not provided | 2022-11-17 | criteria provided, single submitter | clinical testing | BP4 |
| Natera, |
RCV000765887 | SCV001459192 | uncertain significance | Autosomal recessive polycystic kidney disease | 2020-09-16 | no assertion criteria provided | clinical testing |